Upgrade to SI Premium - Free Trial

Protagonist Therapeutics (PTGX)

140.46 +0.14 (0.10%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026 October 27, 2026 7:01 AM - StreetInsider Protagonist Therapeutics (PTGX) PT Raised to $160 at TD Cowen October 21, 2026 8:12 AM - StreetInsider U.S. biotech SMids: Q3 earnings preview October 18, 2026 8:00 PM - StreetInsider UBS Starts Protagonist Therapeutics (PTGX) at Buy October 12, 2026 2:18 AM - StreetInsider Form 4 Protagonist Therapeutics For: Sep 30 Filed by: Ali Asif October 2, 2026 4:10 PM - SEC Filing Form 144 Protagonist Therapeutics Filed by: Ali Asif September 30, 2026 4:20 PM - SEC Filing Form 4 Protagonist Therapeutics For: Sep 08 Filed by: PATEL DINESH V PH D September 10, 2026 9:18 PM - SEC Filing Protagonist Therapeutics launches $300M share repurchase program September 8, 2026 4:05 PM - StreetInsider Protagonist Therapeutics Announces $300 Million Share Repurchase Program September 8, 2026 4:05 PM - StreetInsider Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 September 2, 2026 7:05 AM - StreetInsider Protagonist Therapeutics (PTGX) PT Raised to $190 at BMO Capital September 1, 2026 7:35 AM - StreetInsider Protagonist Therapeutics (PTGX) PT Raised to $170 at H.C. Wainwright September 1, 2026 7:13 AM - StreetInsider Protagonist Therapeutics (PTGX) PT Raised to $180 at Barclays September 1, 2026 4:30 AM - StreetInsider Citi raises Protagonist Therapeutics price target to $182 September 1, 2026 4:07 AM - StreetInsider Clear Street Reiterates Buy Rating on Protagonist Therapeutics (PTGX) August 31, 2026 1:05 PM - StreetInsider Jefferies on Protagonist Therapeutics (PTGX): 'well-funded for multiple high value oral peptide pipeline' August 31, 2026 12:31 PM - StreetInsider Wolfe Research on Protagonist Therapeutics (PTGX): 'We forecast peak sales of $2.9B in 2036' August 31, 2026 10:56 AM - StreetInsider FDA approves Takeda's rusfertide for polycythemia vera treatment August 28, 2026 8:30 PM - StreetInsider Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera August 28, 2026 8:30 PM - StreetInsider Protagonist Therapeutics Reports Granting of Inducement Awards August 18, 2026 4:06 PM - StreetInsider Protagonist Therapeutics (PTGX) PT Raised to $178 at BMO Capital August 17, 2026 8:04 AM - StreetInsider Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C. August 13, 2026 5:19 PM - SEC Filing Form 4 Protagonist Therapeutics For: Aug 10 Filed by: PATEL DINESH V PH D August 12, 2026 6:43 PM - SEC Filing Form 144 Protagonist Therapeutics Filed by: PATEL DINESH V PH D August 10, 2026 4:50 PM - SEC Filing Protagonist Therapeutics (PTGX) PT Raised to $170 at Truist Securities August 10, 2026 7:22 AM - StreetInsider Goldman Sachs Upgrades Protagonist Therapeutics (PTGX) to Buy August 10, 2026 4:12 AM - StreetInsider Form SCHEDULE 13G Protagonist Therapeutics Filed by: STATE STREET CORP August 7, 2026 10:46 AM - SEC Filing Protagonist Therapeutics (PTGX) PT Raised to $153 at Barclays August 6, 2026 4:21 AM - StreetInsider Protagonist Therapeutics (PTGX) Tops Q2 EPS by 16c August 6, 2026 2:34 AM - StreetInsider Form S-8 POS Protagonist Therapeutics August 5, 2026 5:13 PM - SEC Filing Form S-8 POS Protagonist Therapeutics August 5, 2026 5:12 PM - SEC Filing Form S-8 POS Protagonist Therapeutics August 5, 2026 5:11 PM - SEC Filing Form S-8 POS Protagonist Therapeutics August 5, 2026 5:10 PM - SEC Filing Form S-8 POS Protagonist Therapeutics August 5, 2026 5:09 PM - SEC Filing Form S-8 POS Protagonist Therapeutics August 5, 2026 5:08 PM - SEC Filing Form S-8 POS Protagonist Therapeutics August 5, 2026 5:08 PM - SEC Filing Form S-8 POS Protagonist Therapeutics August 5, 2026 5:07 PM - SEC Filing Form S-8 POS Protagonist Therapeutics August 5, 2026 5:06 PM - SEC Filing Form S-8 POS Protagonist Therapeutics August 5, 2026 5:05 PM - SEC Filing Form S-8 POS Protagonist Therapeutics August 5, 2026 5:05 PM - SEC Filing Form S-8 Protagonist Therapeutics August 5, 2026 5:03 PM - SEC Filing Form 10-Q Protagonist Therapeutics For: Jun 30 August 5, 2026 4:21 PM - SEC Filing Form 8-K Protagonist Therapeutics For: Aug 05 August 5, 2026 4:16 PM - SEC Filing Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update August 5, 2026 4:06 PM - StreetInsider Protagonist Therapeutics Reports Granting of Inducement Awards August 4, 2026 4:06 PM - StreetInsider Full Article List